Skip to main content
NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.27%AUDUSD-1.14%GBPCHF+0.99%AUDJPY-0.89%USDCHF+0.84%GBPCAD+0.79%EURGBP-0.66%USDCAD+0.66%GBPNZD+0.64%EURAUD+0.62%AUDNZD-0.62%USDTHB+0.58%EURUSD-0.54%CHFJPY-0.53%NZDUSD-0.53%AUDCAD-0.50%GBPTRY+0.41%GBPJPY+0.41%CADJPY-0.38%NZDCHF+0.33%AUDCHF-0.32%GBPHKD+0.32%EURCHF+0.30%USDTRY+0.29%GBPMXN-0.28%USDJPY+0.27%EURJPY-0.27%NZDJPY-0.24%USDCNH-0.19%CADCHF+0.19%SGDJPY+0.17%PLNJPY+0.17%USDILS+0.16%NOKJPY+0.14%NZDCAD+0.14%EURZAR+0.13%USDZAR+0.13%GBPUSD+0.13%EURCAD+0.12%GBPZAR+0.12%CHFNOK+0.08%EURNOK+0.05%USDMXN+0.04%EURCZK-0.04%USDCOP-0.04%USDNOK+0.04%CHFSGD+0.04%USDHKD+0.04%NZDMXN+0.03%AUDNOK+0.03%CHFSEK+0.03%EURPLN+0.02%USDPLN+0.02%NZDSGD+0.02%AUDDKK-0.02%USDSGD+0.01%EURSGD+0.01%EURHKD-0.01%USDDKK-0.01%USDSEK0.00%EURCNH0.00%EURDKK0.00%AUDSGD0.00%EURNZD0.00%GBPSGD0.00%EURSEK0.00%XPTUSD-0.89%XAGUSD-0.57%GAGUSD-0.57%W1+0.35%HG1-0.32%GAUUSD-0.31%XAUUSD-0.31%C1+0.25%XNGUSD+0.24%UKOIL+0.11%S1-0.04%USOIL-0.02%BTCUSD-0.21%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.07%ZECUSDT+0.69%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.47%XLMUSD+1.62%BCHUSDT-0.42%UNIUSD-0.35%LTCUSD+0.07%HBARUSDT+2.15%SUIUSD+0.79%TONUSD+15.77%TAOUSDT+0.18%AAVEUSD-3.68%DOTUSDT+2.53%ICPUSDT-3.21%ONDOUSDT-0.38%WLDUSDT+10.51%ARBUSDT-0.27%JUPUSDT-0.20%ATOMUSDT+1.34%INJUSDT-2.67%STXUSDT+17.38%FETUSDT+2.30%SEIUSDT+0.33%PYTHUSDT-2.19%TIAUSDT+0.39%IMXUSDT+0.97%GRTUSDT+0.08%OPUSDT+0.54%WIFUSDT+3.46%IOTAUSDT+4.79%POLUSDT-4.26%AXSUSDT+0.76%FARTCOINUSDT-0.41%EOSUSDT+4.76%DYDXUSDT+3.54%GALAUSDT+4.30%ORDIUSDT+1.24%NOTUSDT+1.55%RONINUSDT+0.85%NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.27%AUDUSD-1.14%GBPCHF+0.99%AUDJPY-0.89%USDCHF+0.84%GBPCAD+0.79%EURGBP-0.66%USDCAD+0.66%GBPNZD+0.64%EURAUD+0.62%AUDNZD-0.62%USDTHB+0.58%EURUSD-0.54%CHFJPY-0.53%NZDUSD-0.53%AUDCAD-0.50%GBPTRY+0.41%GBPJPY+0.41%CADJPY-0.38%NZDCHF+0.33%AUDCHF-0.32%GBPHKD+0.32%EURCHF+0.30%USDTRY+0.29%GBPMXN-0.28%USDJPY+0.27%EURJPY-0.27%NZDJPY-0.24%USDCNH-0.19%CADCHF+0.19%SGDJPY+0.17%PLNJPY+0.17%USDILS+0.16%NOKJPY+0.14%NZDCAD+0.14%EURZAR+0.13%USDZAR+0.13%GBPUSD+0.13%EURCAD+0.12%GBPZAR+0.12%CHFNOK+0.08%EURNOK+0.05%USDMXN+0.04%EURCZK-0.04%USDCOP-0.04%USDNOK+0.04%CHFSGD+0.04%USDHKD+0.04%NZDMXN+0.03%AUDNOK+0.03%CHFSEK+0.03%EURPLN+0.02%USDPLN+0.02%NZDSGD+0.02%AUDDKK-0.02%USDSGD+0.01%EURSGD+0.01%EURHKD-0.01%USDDKK-0.01%USDSEK0.00%EURCNH0.00%EURDKK0.00%AUDSGD0.00%EURNZD0.00%GBPSGD0.00%EURSEK0.00%XPTUSD-0.89%XAGUSD-0.57%GAGUSD-0.57%W1+0.35%HG1-0.32%GAUUSD-0.31%XAUUSD-0.31%C1+0.25%XNGUSD+0.24%UKOIL+0.11%S1-0.04%USOIL-0.02%BTCUSD-0.21%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.07%ZECUSDT+0.69%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.47%XLMUSD+1.62%BCHUSDT-0.42%UNIUSD-0.35%LTCUSD+0.07%HBARUSDT+2.15%SUIUSD+0.79%TONUSD+15.77%TAOUSDT+0.18%AAVEUSD-3.68%DOTUSDT+2.53%ICPUSDT-3.21%ONDOUSDT-0.38%WLDUSDT+10.51%ARBUSDT-0.27%JUPUSDT-0.20%ATOMUSDT+1.34%INJUSDT-2.67%STXUSDT+17.38%FETUSDT+2.30%SEIUSDT+0.33%PYTHUSDT-2.19%TIAUSDT+0.39%IMXUSDT+0.97%GRTUSDT+0.08%OPUSDT+0.54%WIFUSDT+3.46%IOTAUSDT+4.79%POLUSDT-4.26%AXSUSDT+0.76%FARTCOINUSDT-0.41%EOSUSDT+4.76%DYDXUSDT+3.54%GALAUSDT+4.30%ORDIUSDT+1.24%NOTUSDT+1.55%RONINUSDT+0.85%
BP

BioMarin Pharmaceutical Inc. (BMRN)

NASDAQ • Healthcare

$60
+$0.13 (+0.2%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$59.9
Day Range$59.37 - $60.71
Avg. Volume (3M)2M
Market Cap$11.5B
P/E Ratio157.9
52 Week Range
$49.26$70.98
Next EarningsIn 25 daysOct 26, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$989.7M100%
Gross Profitminus cost of goods$786.9M80%
Operating Incomeminus R&D and overhead$110.9M11%
Net Incomeminus taxes and the rest$44.7M5%

In plain terms: out of every $100 in revenue, BioMarin Pharmaceutical Inc. keeps $5 as net profit.

Fundamentals & Financials

Revenue (TTM)
$3.4B
Net Income (TTM)
$72.9M
EPS (TTM)
$0.38
ROA (TTM)
0.62%
Current Ratio
2.39

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-241.7%Q1 2026-$0.24
-2.6%Q2 2026$0.76
+26.7%Q3 2026$1.2
Next

Oct 26

in 25 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +26.7%

BioMarin Pharmaceutical beat consensus on both revenue and adjusted EPS in the second fiscal quarter of 2026, reported on August 6, as revenue of $989.7 million against a $932.0 million estimate, +6.2%, and adjusted EPS of $1.20 against a $0.95 estimate, +27%. Revenue rose 20% to about $990 million from $825.4 million a year ago, with VOXZOGO leading at $252.5 million, up 14%, while PALYNZIQ climbed 28% to about $135.2 million. Gross margin held near 80% and operating margin was about 11%, while net income fell 81% to about $45 million from $240.5 million a year ago and adjusted EPS of $1.20 was down 2.4% from $1.23. Operating cash flow was about $168 million, and consensus for the next period calls for EPS of $1.38 on revenue of $1.033 billion.

Next report — what to expect

BioMarin Pharmaceutical Inc. (BMRN) reports next on October 26, 2026. Wall Street’s next-period consensus calls for EPS of $1.34 on revenue of $1.02 billion. For trailing context, revenue increased +19.9% year over year last quarter. BioMarin has beaten EPS in 5 of 8 most recent quarters.

View full earnings history

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing therapies for severe rare disorders and other serious medical conditions. Its products serve genetically defined diseases, and the company generated $3.2 billion of revenue in FY2025. BioMarin trades on the NASDAQ under the ticker BMRN.

Name
BioMarin Pharmaceutical Inc.
CEO
Alexander Hardy
Website
www.biomarin.com
Industry
Healthcare
Year Founded
1996
Employees
3,221

Today's Snapshot

AI-generated

The day ended with BMRN slightly higher at 60.00, while its sector was weaker. BioMarin partnered with Profluent, an AI drug-design company, to design new medicines.

Trading Volume

Below 10d avg (2.1M)

1.7M

vs S&P 500 Today

Inline with Market

+0.03%

Updated: September 30, 2026 at 20:18 UTC

Technical Indicators

2 Buy1 Neutral5 Sell
BMRN leans bearish with the stock below most short and medium moving averages while the 200‑day level remains beneath the current price, indicating longer‑term support but recent weakness. Momentum measures and MACD are negative and CCI is notably depressed, while RSI sits in lower territory; ADX shows only modest trend strength and ATR indicates moderate volatility. On‑balance volume is soft and the pivot lies near the market, so downside bias is present but not overwhelming. Technical takeaway: Sell.
All signals
  • EMA (5 indicators)$59.22 - $62.95
    Sell
  • RSI (14)34.29
    Neutral
  • Stochastic %K (14, 3, 3)12.74
    Buy
  • MACD Level (12, 26)-1.26
    Sell

Peers & Related Assets

MRNAModerna, Inc.
$192.57-5.3%
RVMDRevolution Medicines, Inc.
$205.26+0.4%
EXELExelixis, Inc.
$58.41-0.4%
HALOHalozyme Therapeutics, Inc.
$110.4-1.0%
BBIOBridgeBio Pharma, Inc.
$65.8-0.3%
MDGLMadrigal Pharmaceuticals, Inc.
$503.96-1.1%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.